Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2022-03-17 00:00:00 ET · period of report 2022-03-15 · accession 0001214659-22-004087 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-17 | 2022-03-15 | ALLO | Amado Rafael | CMO, EVP of R, D | S - Sale | $7.71 | -5,169 | 320.1K | -2% | -$39.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-15 | S | D | 5,169 | $7.71 | 320,119 | D | — | — | (F1) Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.69 to $7.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. (F3) Includes 1360 shares of the Issuer's common stock acquired by the reporting person on March 15, 2022 pursuant to an employee stock purchase program. |